About
Genaphora has developed real-time, quantitative PCR (qPCR) and end-point PCR diagnostic kits. The company has developed its own computational biology platform employing thermodynamics calculations and modifications of linguistic complexity. Genaphoras approach ensures the best fit primers and probes out of a whole genome sequence of any given organism, resulting in greater sensitivity and specificity. The AquatiqPCR is based on Genaphoras patented chimeric DNA/RNA primer/probes technology and proprietary computational platform, and offers highly specific, supersensitive detection down to a single cell. AquatiqPCR can detect E. coli, Cryptosporidium, and Giardia in water samples.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Genaphora's primary focus in terms of product development?
- Genaphora has developed real-time, quantitative PCR (qPCR) and end-point PCR diagnostic kits for pathogen detection in drinking and source water.
- What is the operational status of Genaphora?
- Genaphora is currently inactive and ceased to operate in October 2022.
- When was Genaphora founded and where is its headquarters located?
- Genaphora was founded in February 2008 and is headquartered in Tel Aviv-Yafo, Israel.
- What is the core technology behind Genaphora's AquatiqPCR product?
- The AquatiqPCR product is based on Genaphora's patented chimeric DNA/RNA primer/probes technology and a proprietary computational platform.
- Which pathogens can Genaphora's AquatiqPCR detect in water samples?
- AquatiqPCR can detect E. coli, Cryptosporidium, and Giardia in water samples.
- Has Genaphora received any grants?
- Yes, Genaphora received a grant from the IIA in December 2009.
- Who are the founders of Genaphora?
- The founders of Genaphora are Kobi Inbar and Ofer Peleg.
- What was a notable event involving Genaphora in May 2010?
- In May 2010, Mekorot's WaTech unit presented Genaphora, among other startups, to IBM.